Tocqueville Asset Management L.P. decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 23.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,178 shares of the company’s stock after selling 8,705 shares during the period. Tocqueville Asset Management L.P.’s holdings in Eli Lilly and were worth $2,401,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Waldron LP boosted its position in shares of Eli Lilly and by 46.7% during the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after acquiring an additional 1,574 shares in the last quarter. Davis R M Inc. boosted its position in shares of Eli Lilly and by 3.1% during the 1st quarter. Davis R M Inc. now owns 13,827 shares of the company’s stock worth $1,163,000 after acquiring an additional 410 shares in the last quarter. Pinnacle Financial Partners Inc. boosted its position in shares of Eli Lilly and by 10.7% during the 1st quarter. Pinnacle Financial Partners Inc. now owns 34,952 shares of the company’s stock worth $2,940,000 after acquiring an additional 3,378 shares in the last quarter. Solaris Asset Management LLC boosted its position in shares of Eli Lilly and by 165.0% during the 1st quarter. Solaris Asset Management LLC now owns 2,650 shares of the company’s stock worth $223,000 after acquiring an additional 1,650 shares in the last quarter. Finally, Strategic Advisors LLC acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $396,000. Institutional investors and hedge funds own 75.53% of the company’s stock.

Eli Lilly and Company (NYSE LLY) opened at 85.95 on Tuesday. The company has a market cap of $90.68 billion, a P/E ratio of 37.19 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The stock’s 50 day moving average is $83.56 and its 200 day moving average is $82.19.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the business posted $0.86 EPS. The company’s revenue was up 7.8% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.

Several research firms recently issued reports on LLY. Barclays PLC increased their price target on shares of Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Thursday, July 27th. Jefferies Group LLC reiterated a “buy” rating and set a $96.00 price target (up previously from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Finally, Cowen and Company reiterated a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $88.97.

TRADEMARK VIOLATION NOTICE: “Tocqueville Asset Management L.P. Has $2.40 Million Position in Eli Lilly and Company (LLY)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/17/tocqueville-asset-management-l-p-has-2-40-million-position-in-eli-lilly-and-company-lly.html.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 990,000 shares of company stock worth $82,949,650 over the last quarter. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.